Debra Borchardt at Green Market News stories….
Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: MYCOF) has entered into an settlement to purchase Canadian-based NeuroPharm Inc. in a deal valued at roughly $6.three million. NueroPharm is a developer of pure psychedelic-based remedies for psychological well being problems. Mydecine just lately signed an agreement with Applied Pharmaceutical Innovation (API), a translational business drug institute on the University of Alberta’s Faculty of Pharmacy and Pharmaceutical Sciences because it makes quick progress within the psilocybin world.
Colonel (Ret’d) Pucci, CEO of NeuroPharm stated, “Our mission is to develop and bring to market treatments addressing the mental health conditions frequently experienced by veterans, including PTSD, depression, and anxiety. We understand the unique circumstances of the veteran community and are devoted to treating these substantial unmet needs. Our collaborative partnership with Mydecine will accelerate our ability to address the enormous challenge of restoring the overall wellness in the veteran, EMS and frontline personnel communities.”
NeuroPharm stated in a press release that it’s centered on growing distinctive and proprietary applied sciences to deal with varied psychological well being circumstances regularly skilled by veterans and frontline employees akin to PTSD, despair, habit, anxiousness, and panic problems in addition to migraine and cluster complications. The group is a mix of critically acclaimed scientists and navy personnel boasting in depth drug improvement expertise and deep, embedded relationships throughout the Canadian and U.S. militaries.
Read Debra’s full report at